Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-1800 +/- INO-9112 in Chronic Hepatitis B
NCT02431312Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jan 2015
- Primary completion
- May 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 8
01
Overview
Phase 1, randomised, open-label trial of INO-1800 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoint: Safety Assessment (Composite of multiple measures: pain (VAS), adverse events, lab abnormalities, changes in vital signs) up to 76 weeks. Started Jan 2015; status: completed.
02
Drugs
INO-1800
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02431312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431312.